Patient orientated research and clinical trials

Research output: Contribution to journalArticle

Abstract

The time is now ripe for the ALS community in the United States to set up a national ALS Study Group. NIH and other granting agencies should fund a program to set up and run the ALS Study Group for five years renewable. This program should result in a competitive request for applications. The benefits likely to derive from a national ALS Study Group would include cheaper and more cost-effective clinical therapeutic trials, the development of better techniques for pilot trials, an increased number of potential new drugs brought from bench to bedside for ALS trials, increased research on biological and surrogate markers of disease, and increased physician-initiated research.

Original languageEnglish
Pages (from-to)137-140
Number of pages4
JournalAmyotrophic Lateral Sclerosis and Other Motor Neuron Disorders
Volume5
Issue numberSUPPL. 1
DOIs
StatePublished - Sep 1 2004

Fingerprint

Biomarkers
Clinical Trials
Financial Management
Research
Physicians
Costs and Cost Analysis
Pharmaceutical Preparations
Therapeutics

Keywords

  • ALS Study Group
  • Clinical trials
  • New drug development
  • Physician-initiated research

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Patient orientated research and clinical trials. / Bradley, Walter G.

In: Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, Vol. 5, No. SUPPL. 1, 01.09.2004, p. 137-140.

Research output: Contribution to journalArticle

@article{4704d44c54674d228c8749a1307b45f1,
title = "Patient orientated research and clinical trials",
abstract = "The time is now ripe for the ALS community in the United States to set up a national ALS Study Group. NIH and other granting agencies should fund a program to set up and run the ALS Study Group for five years renewable. This program should result in a competitive request for applications. The benefits likely to derive from a national ALS Study Group would include cheaper and more cost-effective clinical therapeutic trials, the development of better techniques for pilot trials, an increased number of potential new drugs brought from bench to bedside for ALS trials, increased research on biological and surrogate markers of disease, and increased physician-initiated research.",
keywords = "ALS Study Group, Clinical trials, New drug development, Physician-initiated research",
author = "Bradley, {Walter G}",
year = "2004",
month = "9",
day = "1",
doi = "10.1080/17434470410019708",
language = "English",
volume = "5",
pages = "137--140",
journal = "Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration",
issn = "2167-8421",
publisher = "Informa Healthcare",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Patient orientated research and clinical trials

AU - Bradley, Walter G

PY - 2004/9/1

Y1 - 2004/9/1

N2 - The time is now ripe for the ALS community in the United States to set up a national ALS Study Group. NIH and other granting agencies should fund a program to set up and run the ALS Study Group for five years renewable. This program should result in a competitive request for applications. The benefits likely to derive from a national ALS Study Group would include cheaper and more cost-effective clinical therapeutic trials, the development of better techniques for pilot trials, an increased number of potential new drugs brought from bench to bedside for ALS trials, increased research on biological and surrogate markers of disease, and increased physician-initiated research.

AB - The time is now ripe for the ALS community in the United States to set up a national ALS Study Group. NIH and other granting agencies should fund a program to set up and run the ALS Study Group for five years renewable. This program should result in a competitive request for applications. The benefits likely to derive from a national ALS Study Group would include cheaper and more cost-effective clinical therapeutic trials, the development of better techniques for pilot trials, an increased number of potential new drugs brought from bench to bedside for ALS trials, increased research on biological and surrogate markers of disease, and increased physician-initiated research.

KW - ALS Study Group

KW - Clinical trials

KW - New drug development

KW - Physician-initiated research

UR - http://www.scopus.com/inward/record.url?scp=6444235050&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=6444235050&partnerID=8YFLogxK

U2 - 10.1080/17434470410019708

DO - 10.1080/17434470410019708

M3 - Article

C2 - 15512898

AN - SCOPUS:6444235050

VL - 5

SP - 137

EP - 140

JO - Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

JF - Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

SN - 2167-8421

IS - SUPPL. 1

ER -